Haemonetics (HAE) Stock Price, News & Analysis

Company Overview

Haemonetics Corporation, headquartered in Braintree, Massachusetts, specializes in blood management solutions that support the collection, processing and transfusion of blood and blood components. The company’s portfolio includes apheresis systems, blood recovery devices, hemostasis monitoring products and a suite of software tools designed to enhance patient safety and operational efficiency. Haemonetics serves hospitals, blood banks and plasma collection facilities by delivering consumables, disposables and integrated information platforms that streamline workflows and ensure regulatory compliance.

Founded in 1971, Haemonetics has grown through a combination of in-house innovation and targeted acquisitions. Early milestones in plasma separation technologies set the stage for subsequent developments in automated blood processing and real-time data analytics. Over the decades, the company has expanded its capabilities via strategic purchases of complementary businesses, strengthening its position in transfusion medicine, surgical blood salvage and patient blood management.

With operations spanning more than 100 countries, Haemonetics maintains manufacturing and research facilities in North America, Europe and Asia Pacific. This global footprint enables the company to provide localized customer support, rapid delivery of critical supplies and adherence to regional regulatory requirements. Its software platforms offer inventory tracking, quality control and reporting functions, helping clients optimize inventory levels, reduce waste and improve clinical outcomes.

Under the leadership of President and Chief Executive Officer Tim S. Ring, Haemonetics continues to invest in research and development to address evolving needs in healthcare. The executive team’s combined expertise in medical technology, operations and global markets drives the company’s commitment to advancing patient blood management. By focusing on innovation, service and collaboration, Haemonetics aims to deliver solutions that enhance transfusion safety and operational performance for healthcare providers worldwide.

Key Stats

• Today's Range: $76.28 to $77.33
• 50-Day Range: $62.55 to $76.85
• 52-Week Range: $55.30 to $94.99
• Volume: 249,556 shs
• Average Volume: 673,113 shs
• Market Capitalization: $3.69 billion
• P/E Ratio: 23.22
• Dividend Yield: N/A
• Price Target: $96.80
• Consensus Rating: Moderate Buy

Haemonetics Stock Analysis - MarketRank™

Haemonetics scored higher than 97% of companies evaluated by MarketBeat, and ranked 39th out of 922 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 4.5 / 5
• Analyst Rating: Moderate Buy

Consensus Rating

Haemonetics has received a consensus rating of Moderate Buy. The company's average rating score is 2.91, and is based on 7 buy ratings, 1 hold rating, and 1 sell rating.

Amount of Analyst Coverage

Haemonetics has been the subject of 5 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

Earnings and Valuation

• Score: 2.5 / 5
• Proj. Earnings Growth: 10.77%

Earnings Growth

Earnings for Haemonetics are expected to grow by 10.77% in the coming year, from $4.55 to $5.04 per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Haemonetics is 23.22, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 25.66.

Price to Earnings Ratio vs. Sector

The P/E ratio of Haemonetics is 23.22, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 27.69.

Price to Earnings Growth Ratio

Haemonetics has a PEG Ratio of 1.25. PEG Ratios above 1 indicate that a company could be overvalued.

Price to Book Value per Share Ratio

Haemonetics has a P/B Ratio of 4.70. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Short Interest

• Score: 2.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

8.57% of the float of Haemonetics has been sold short.

Short Interest Ratio / Days to Cover

Haemonetics has a short interest ratio ("days to cover") of 6.8.

Change versus previous month

Short interest in Haemonetics has recently decreased by 1.46%, indicating that investor sentiment is improving.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Haemonetics does not currently pay a dividend.

Dividend Growth

Haemonetics does not have a long track record of dividend growth.

Sustainability and ESG

• Score: 4.3 / 5
• Environmental Score: -0.54

Percentage of Shares Shorted

8.57% of the float of Haemonetics has been sold short.

Short Interest Ratio / Days to Cover

Haemonetics has a short interest ratio ("days to cover") of 6.8.

Change versus previous month

Short interest in Haemonetics has recently decreased by 1.46%, indicating that investor sentiment is improving.

News and Social Media

• Score: 2.4 / 5
• News Sentiment: 1.35

News Sentiment

Haemonetics has a news sentiment score of 1.35. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.58 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 2 news articles for Haemonetics this week, compared to 7 articles on an average week.

Search Interest

Only 2 people have searched for HAE on MarketBeat in the last 30 days. This is a decrease of 0% compared to the previous 30 days.

Company Ownership

• Score: 1.7 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Haemonetics insiders have not sold or bought any company stock.

Percentage Held by Insiders

Only 1.84% of the stock of Haemonetics is held by insiders.

Percentage Held by Institutions

99.67% of the stock of Haemonetics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

HAE Stock Analysis - Frequently Asked Questions

How have HAE shares performed this year?

Haemonetics' stock was trading at $78.08 at the beginning of the year. Since then, HAE shares have decreased by 1.6% and is now trading at $76.8450.

How were Haemonetics' earnings last quarter?

Haemonetics Corporation (NYSE:HAE) issued its earnings results on Thursday, May, 8th. The medical instruments supplier reported $1.24 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $1.22 by $0.02. The business's revenue for the quarter was down 3.5% compared to the same quarter last year.
Read the conference call transcript.

Who are Haemonetics' major shareholders?

Top institutional shareholders of Haemonetics include Confluence Investment Management LLC (0.08%) and Central Pacific Bank Trust Division (0.02%). Insiders that own company stock include Michelle L Basil, Anila Lingamneni, Josep Llorens, Stewart W Strong and Laurie A Miller.
View institutional ownership trends.

How do I buy shares of Haemonetics?

Shares of HAE stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Haemonetics own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Haemonetics investors own include Humana (HUM), American Water Works (AWK), Waste Connections (WCN), Voyager Therapeutics (VYGR), DiamondRock Hospitality (DRH), The RMR Group (RMR) and AU Optronics (AUOTY).

Company Calendar

• Last Earnings: 5/08/2025
• Today: 7/06/2025
• Next Earnings (Estimated): 8/14/2025
• Fiscal Year End: 3/31/2026

Industry, Sector and Symbol

• Stock Exchange: NYSE
• Sector: Medical
• Industry: MED PRODUCTS
• Sub-Industry: Health Care Supplies
• Current Symbol: NYSE:HAE
• CIK: 313143
• Web: www.haemonetics.com
• Phone: (781) 848-7100
• Fax: 781-848-5106
• Employees: 3,023
• Year Founded: 1971

Price Target and Rating

• Average Stock Price Target: $96.80
• High Stock Price Target: $116.00
• Low Stock Price Target: $68.00
• Potential Upside/Downside: +26.0%
• Consensus Rating: Moderate Buy
• Rating Score (0-4): 2.91
• Research Coverage: 11 Analysts

Profitability

• EPS (Trailing Twelve Months): $3.31
• Trailing P/E Ratio: 23.22
• Forward P/E Ratio: 16.89
• P/E Growth: 1.25
• Net Income: $167.68 million
• Net Margins: 12.32%
• Pretax Margin: 15.58%
• Return on Equity: 26.37%
• Return on Assets: 9.22%

Debt

• Debt-to-Equity Ratio: 1.12
• Current Ratio: 1.62
• Quick Ratio: 0.99

Sales & Book Value

• Annual Sales: $1.36 billion
• Price / Sales: 2.71
• Cash Flow: $7.20 per share
• Price / Cash Flow: 10.67
• Book Value: $16.34 per share
• Price / Book: 4.70

Miscellaneous

• Outstanding Shares: 48,040,000
• Free Float: 47,157,000
• Market Cap: $3.69 billion
• Optionable: Optionable
• Beta: 0.39